



## Company overview

- Breakthrough platform technology for oral delivery of drugs and vaccines presently available only via injection
- Pipeline currently focused on diabetes, with potential for a variety of additional treatment indications addressing multi-billion-dollar markets
- Oramed's lead product, oral insulin (ORMD-0801), has potential to be the first commercial oral insulin
- Phase 3 studies under US FDA underway
- JV, Oravax Medical ([www.ora-vax.com](http://www.ora-vax.com)), developing oral Covid-19 vaccine

### EQUITY OVERVIEW

(as of 12/04/22)

**Nasdaq/TASE: ORMP**

**Price: ~\$8.65**

**Market Cap: \$338.34 M**

**52 Week Range: \$3.59-\$17.64**

**Avg. Daily Volume (90 day):  
270K**

**Shares Outstanding: ~39M**  
(as of 09/30/22)

**Cash/Investments: ~\$160M**  
(as of 09/30/22)

### ANALYST COVERAGE

- H.C. Wainwright & Co.
- Aegis Capital
- Zacks
- AGP
- Canaccord
- Cantor Fitzgerald

### UNMET NEED IN DIABETES

- **1 in 10 adults** has diabetes
- **10% of U.S. Healthcare dollars** is spent on diabetes
- **Every 5 seconds** 1 adult dies from diabetes

### INVESTMENT HIGHLIGHTS

#### Breakthrough Platform Technology Delivers Injectable Drugs Orally

Oramed's unique Protein Oral Delivery (POD™) technology enables proteins, such as insulin, to travel through the gastrointestinal tract and into the bloodstream. This method is more natural and should eliminate many of the negative side-effects of injection delivery. The oral administration of current injection-only therapies for conditions including diabetes should offer clear benefits, including, increased compliance and safety, fewer side effects and greater comfort for patients.

#### Addressing \$483 Billion Market with Oral Formulations

Roughly \$483 billion worth of drugs and vaccines are currently delivered via injection. This includes the diabetes market where \$34.8 billion of insulin and \$11.3 billion of GLP-1 analogs were sold globally in 2019. The vaccine market size was approximately \$61 billion in 2021 and is expected to surpass \$125 billion by 2028.

#### Oral Treatment has the Potential to Curb Progression of Type 2 Diabetes

ORMD-0801 has the potential to create a new paradigm in the treatment of type 2 diabetes by orally delivering insulin even at an earlier stage of treatment. Earlier treatment should slow disease progression and delay late-stage complications. Oramed successfully completed a Phase 2b, 90-day HbA1c trial of ORMD-0801, which met its primary endpoint achieving a statistically significant reduction of HbA1c. Oramed has initiated Phase 3 trials under the FDA and is pursuing a Biologics License Application (BLA) regulatory pathway for ORMD-0801 which would grant a full 12 years of marketing exclusivity, if approved.

#### Oral Covid-19 Vaccine in Development

Oravax Medical, founded on Oramed's and Premas Biotech's cutting-edge technology is developing an oral Covid-19 vaccine. Oravax's COVID-19 oral vaccine candidate benefits from being a virus like particle (VLP) triple antigen vaccine that targets three structural proteins, which should make it a better candidate for protection across emerging mutations of the coronavirus.

### 2023 ANTICIPATED MILESTONES

<b>ORMD-0801: Oral Insulin</b>	<ul style="list-style-type: none"> <li>• First Phase 3 oral insulin trial top-line data</li> <li>• 100% enrolment of 2<sup>nd</sup> Phase 3 oral insulin trial</li> </ul>
<b>ORMD-0901: Oral GLP-1</b>	<ul style="list-style-type: none"> <li>• Bioavailability study in diabetes patients</li> </ul>
<b>Oravax Medical: Oral Vaccine</b>	<ul style="list-style-type: none"> <li>• Phase 1 data for oral Covid-19 vaccine</li> </ul>

Disclaimer: Except for historical information contained herein, the statements in this fact sheet are "forward-looking" within the meaning of the Private Securities Litigation Act of 1995. A fuller discussion of Oramed Pharmaceuticals Inc.'s risks and uncertainties are described in the Company's filings with the Securities and Exchange Commission, which should be reviewed in conjunction with this overview

